Drug-Refractory Trigeminal Neuralgia: Treatment via Botulinum Toxin Type A by Bohluli, Behnam et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Drug-Refractory Trigeminal Neuralgia: Treatment via
Botulinum Toxin Type A
Behnam Bohluli,
Mohammad Hosein Kalantar Motamedi,
Misaq Heydari and Milad Heydari
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/63258
Abstract
Trigeminal neuralgia (TN) is a disorder characterized by severe abrupt lancinating
pains, limited to areas of distribution of the fifth cranial nerve—the trigeminal nerve.
Numerous modals have been used to reduce or alleviate the intensity and frequency of
pain. Drug therapy with anticonvulsive drugs is still the first choice. Migraine and
occipital neuralgia have been treated via botulinum toxin type A (BTX-A). Symptoms
of TN (pain duration, initiating factors, affected nerve branch, frequency of attacks, and
severity of pain) are assessed before injections, and evaluated 1 week, 1 month, and 6
months after injection of 50 U reconstituted BTX-A solution in the trigger zones. Patients
generally improve with regard to frequency and severity of pain attacks and in many,
the pain is completely eradicated and there is no need for further medication. In some
patients, nonsteroidal anti-inflammatory drugs (NSAIDs) may be needed to alleviate
pain attacks. All patients develop higher pain thresholds after injections. Complica‐
tions of BTX therapy include transient paresis of the facial nerve. BTX-A therapy is a
minimally invasive method that  can play a role in treating TN before other more
invasive therapies, i.e., radiofrequency and surgery, are sought. In this chapter, we
discuss the indication and method to treat TN via BTX-A in patients refractory to
medical treatment.
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1. Introduction
The prevalence of trigeminal neuralgia (TN) in the population is about 1 in 25,000 people, and
is slightly more in women. Patients are usually in midlife or older [1]. Numerous modals have
been used to reduce or alleviate pain intensity and frequency. Drug therapy using anticon‐
vulsive drugs is usually the first choice. Surgery (i.e., microvascular decompression [MVD],
stereotactic  rhizotomy,  percutaneous  balloon  compression,  and  other  methods)  may  be
indicated [2]. Some of these treatment modalities may have severe complications. Confronta‐
tion of patients presenting with refractory cases also known as drug-refractory trigeminal
neuralgia (DR-TN) show that further research is still warranted [3]. Botulinum toxin type A
(BTX-A) is used to treat pains such as occipital neuralgia and migraine [4]. We have used BTX-
A to treat DR-TN with good results.
1.1. Diagnosis
Patients were treated for DR-TN clinically documented according to the criteria defined for
TN by the International Headache Society [5] and Winn’s criteria (presence of paroxysmal
unilateral sharp stabbing pain limited to a branch or branches of the trigeminal nerve, painful
trigger zones (TZs), frequent pain-free intervals between paroxysms, unresponsive to anti‐
convulsants, and no neurologic deficit). Patients with a musculoskeletal disorder (considered
to be a relative contraindication for BTX-A injection) or with a history of a surgical procedure
on the cranial base for TN or pathologies (e.g., tumors) were not treated.
1.2. Trigger zones
TZs were identified by the patients and by clinical examination. Injection of lidocaine into TZs
can both confirm the diagnosis (when the pain stops) and guide us to where we can inject the
BTX (ensuring that we do not inject in the area of the branches of the facial nerve).
2. Treatment
Patients who have undergone medical treatment protocols (carbamazepine, antiepileptic
drugs like gabapentin, cannabinoids, etc., for months to a year) can be treated with BTX-A. If
they are or become ineffective then the patient is first injected with 1.8 ml lidocaine at the TZ.
Injection of lidocaine into TZs alleviates the pain until the anesthetic wears off [6]. Pain recurs
after the duration of the local anesthetic. This also ensures that the injection site (the TZ) is not
on the facial nerve. The possibility of transient paresis is explained to the patients. Patient
demographics, age, gender, presence of TZ, involvement site, involved nerve branch, total/
partial success (after injection), and complications are documented. Pain symptoms, duration,
provoking factors, nerve branch involved, frequency of attacks (per day), and pain severity
(via visual analog scale) are documented just before injections and after 1 week, 1 month, and
6 months. The overall response to treatment is assessed and compared with that at baseline
(before injection) [6].
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2.1. Technique
2.1.1. Preparation of the injection
Hundred patients between 22 and 70 years of age suffering from TN were treated at our center.
The patients were first injected with 1.8 ml lidocaine at the TZ. This alleviates the pain until
the anesthetic wears off [6]. This also ensures that the trigger point is not on the facial nerve.
Three milliliters of normal saline solution is mixed in a vial of BTX-A; a fresh solution is
prepared; 50 U of reconstituted BTX-A is injected at the TZs.
3. Outcomes
Data and pain characteristics of 100 patients between 22 and 70 years (mean 47 years) of age
who were suffering from TN for 3 months to 24 years are presented in Table 1. In 35 patients,
the mandibular nerve alone was the origin of pain and in 38 patients, it was the maxilla nerve.
More than 1 branch of the trigeminal nerve was involved in 28 patients (both maxilla and
mandible nerves in 4 patients, both maxilla and ophthalmic nerves in 1 patient). The ophthal‐
mic nerve alone was involved in 5 patients. All of the patients improved regarding frequency
and severity of pain attacks up to 6 months after injection (Table 2). In 35 patients, pain was
completely eradicated; there was no need for further medication. In 34 patients, nonsteroidal
anti-inflammatory drugs (NSAIDs) were enough to alleviate pain attacks, and 25 patients
became responsive to anticonvulsive drugs after injection. Six months after the injection, a
significant improvement in all the patients in the patient global assessment scale was seen.
Complications included transient paresis of the buccal branch of the facial nerve in 3 patients;
in 7 of them, it was not significant and resolved in 2 weeks; in the third patient, the paresis was









1 M 67 Spontaneous 36 x Transient partial
paralysis
2 M 28 Spontaneous 6 X x ----
3 F 55 Spontaneous 24 × Transient partial
paralysis
4 M 62 Spontaneous 60 x ----
5 M 32 Spontaneous 12 × ----
6 M 48 Cold-Spontaneous 288 x × ----
7 F 45 Touch-cold-stress 24 × × ----
8 M 53 Speaking 48 × ----
9 M 65 Spontaneous 8 x ----
10 F 60 Spontaneous 60 x ----











11 F 29 Spontaneous-stress 18 x x ----
12 M 34 Spontaneous 24 x ----
13 F 46 Spontaneous 6 x ----
14 F 51 Spontaneous 96 x ----
15 F 58 Spontaneous 24 x x Transient partial
paralysis
16 F 45 Spontaneous-stress 36 X X ----
17 M 65 Spontaneous 12 x ----
18 F 22 Spontaneous 6 x ----
19 M 70 Stress-touch 48 x ----
20 M 34 Spontaneous-touch 12 x ----
21 F 48 Spontaneous 6 x ----
22 M 61 Speaking-touch 48 x ----
23 M 66 Spontaneous 240 x ----
24 F 71 Spontaneous 8 X ----
25 F 65 Spontaneous 48 x ----
26 F 35 Speaking 48 x ----
27 M 46 Spontaneous 36 x x ----
28 M 73 Spontaneous 240 x ----
29 F 51 Spontaneous 12 x ----
30 F 65 Spontaneous-touch-
Speaking
120 x ----
31 M 74 Spontaneous 60 x ----
32 F 35 Spontaneous 6 X ----
33 F 55 Spontaneous 18 X ----
34 M 31 Spontaneous 12 X ----
35 M 59 Spontaneous 60 x ----
36 M 42 Spontaneous-touch 9 x ----
37 F 46 Spontaneous 12 ----
38 F 32 Spontaneous 18 x X ----
39 F 64 Spontaneous-touch 12 x ----
40 M 66 Spontaneous 180 x X ----
41 M 44 Spontaneous 24 X ----









42 M 71 Spontaneous-stress 240 X Transient partial
paralysis
43 F 65 Spontaneous 9 x ----
44 F 42 Spontaneous 120 x x ----
45 M 44 Spontaneous 24 X X ----
46 F 53 Spontaneous 48 X ----
47 F 32 Spontaneous 12 X ----
48 M 32 Spontaneous 12 x ----
49 M 65 Spontaneous 12 x X ----
50 F 46 Cold-Touch 6 × ----
Table 1. Demographic data and pain characteristic of TN patients.
Patient Severity of pain (VAS) Frequency of attacks (per d)  Global assessment (after 6 mo)
S0 S1 S2 F0 F1 F2
1 10 3 2 60 5 3 3
2 8 0 0 10 0 0 4
3 7 2 2 25 2 3 4
4 10 4 2 40 5 5 3
5 9 0 0 20 0 0 4
6 6 0 0 30 0 0 3
7 7 0 0 15 0 0 4
8 5 0 0 45 0 0 4
9 10 5 5 50 10 10 1
10 9 2 2 60 5 8 3
11 5 0 0 5 0 0 4
12 8 2 1 10 2 2 4
13 10 3 2 50 20 20 2
14 6 0 0 25 0 0 4
15 10 2 2 50 5 10 3
16 7 1 1 22 3 3 RECENT CASE< 6 MO
17 5 2 1 12 1 2 RECENT CASE< 6 MO
18 8 0 0 16 0 0 RECENT CASE< 6 MO
19 10 3 3 34 2 2 RECENT CASE< 6 MO
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Patient Severity of pain (VAS) Frequency of attacks (per d)  Global assessment (after 6 mo)
S0 S1 S2 F0 F1 F2
20 4 0 0 10 0 0 RECENT CASE< 6 MO
21 8 1 1 35 4 4 RECENT CASE< 6 MO
22 9 0 0 50 0 0 RECENT CASE< 6 MO
23 10 3 3 30 1 3 RECENT CASE< 6 MO
24 6 0 0 50 0 0 RECENT CASE< 6 MO
25 4 1 1 25 1 3 RECENT CASE< 6 MO
26 8 2 2 20 5 5 RECENT CASE< 6 MO
27 10 3 1 35 5 5 RECENT CASE< 6 MO
28 7 0 0 10 0 0 RECENT CASE< 6 MO
29 6 3 4 15 10 10 RECENT CASE< 6 MO
30 8 2 2 10 3 2 RECENT CASE< 6 MO
31 5 1 1 40 15 20 RECENT CASE< 6 MO
32 10 3 4 15 3 3 RECENT CASE< 6 MO
33 7 0 0 35 10 10 RECENT CASE< 6 MO
34 3 0 0 20 5 8 RECENT CASE< 6 MO
35 6 0 0 25 0 0 RECENT CASE< 6 MO
36 10 3 3 60 10 10 RECENT CASE< 6 MO
37 8 0 0 20 0 0 RECENT CASE< 6 MO
38 6 3 3 40 5 5 RECENT CASE< 6 MO
39 10 0 0 50 0 0 RECENT CASE< 6 MO
40 7 0 0 30 0 0 RECENT CASE< 6 MO
41 6 4 4 30 10 15 RECENT CASE< 6 MO
42 9 1 1 20 5 5 RECENT CASE< 6 MO
43 10 5 5 30 10 10 RECENT CASE< 6 MO
44 5 0 0 50 0 0 RECENT CASE< 6 MO
45 8 3 3 60 30 30 RECENT CASE< 6 MO
46 10 0 0 30 0 0 RECENT CASE< 6 MO
47 4 0 0 15 0 o RECENT CASE< 6 MO
48 7 5 6 25 20 20 RECENT CASE< 6 MO
49 9 1 1 30 2 3 RECENT CASE< 6 MO
50 8 0 0 60 0 0 RECENT CASE< 6 MO
Table 2. Pain severity and frequency during the course of treatment.
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Because TN is a painful neuropathic disorder, it typically presents as paroxysmal or abrupt
facial pain lasting from seconds to several minutes and rarely up to hours. The pain is described
as stabbing electric shocks occurring spontaneously or after stimulation of a TZ. Idiopathic TN
is seen in 1 in 100,000 people and more frequently in those aged more than 50 years. It may be
typical (paroxysmal pain only) or atypical (association of a permanent background of pain).
The facial skin is painful upon attacks in the area innervated by V1, V2, or V3 of the trigeminal
nerve. An etiology often cannot be found. Pain is severe and may begin while talking or
swallowing. Analgesics are usually ineffective. There may be a trigger point in the oral cavity
that sparks the attack [7]. Treatment of TN is possible via medication or surgery.
4. Differentiation of dental pain and trigeminal neuralgia
4.1. Dental pain
Pulpitis or periapical infection can result in severe dental pain. In pulpitis, the patient often
has nocturnal pain exacerbated by heat; radiographic findings may present caries or deep
restorations. In a patient with the mentioned radiographic findings or endodontic treatment,
there may be pain from a periapical infection not yet apparent on radiographs. In this case, the
tooth may be felt to be extruded and painful upon percussion and to palpation over the apex
of the tooth root in the vestibule; however, pain does not involve the facial skin. In dental pain,
the cause is often apparent and the pain usually responds to analgesics. Radiographic findings
are usually diagnostic and the origin of pain to the oral cavity, tooth or gum can be traced.
4.2. Trigeminal neuralgia pain
The pain from TN is said to feel like stabbing, electric shocks occurring spontaneously or
following a TZ stimulation. TN pain is excruciating; this neuropathic disorder presents
typically as paroxysmal or abrupt attacks lasting from seconds to one or more minutes and
rarely up to several hours [7]. Idiopathic TN occurs in 1 in 100,000 people and is more
frequently found in patients aged more than 50 years. It may be typical (i.e., with only
paroxysmal pain) or atypical (i.e., association with a permanent background of pain). The skin
of the face is painful upon TN attacks in the area innervated by V1, V2, or V3 of the trigeminal
nerve; radiographic findings are often lacking and pain is not necessarily nocturnal. Often an
etiology is not found. Pain is severe and may ensue when talking or swallowing. Analgesics
are usually ineffective. Radiographs are not diagnostic and the origin of pain cannot be traced
to the oral cavity upon examination. However, a trigger point in the oral cavity may be found
that sparks the attack.
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5. Other treatment approaches
5.1. Medical treatment approach
A medical approach is often used primarily in an attempt to treat TN noninvasively. This is
usually accomplished using anticonvulsants. Carbamazepine is the classic medication chosen
for this purpose. However, long-term studies have shown a gradual decrease in efficacy. Initial
response is 80%. After 10 years, its effectiveness decreases by 50% [7]. Other antiepileptic drugs,
such as gabapentin and cannabinoids, have also been used.
5.2. Neurectomy
Another method to treat TN is neurectomy. It has been reported to be successful in 88.2%
patients. Balloon compression is another method used to treat TN, for which initial pain relief
has been reported in 93% patients. Unilateral facial sensory loss has been reported in 61% of
these patients [7].
5.3. Microvascular decompression
Use of MVD for TN which is caused by venous pressure is another effective method of
treatment; pain recurrence ranges from 31.0% to 75%, within 1 to 3 years after operation, owing
to development of new veins around the nerve root in 87.5% patients. Lee [8] did an electronic
search of patient records from 1988 to 1998 and found that in 393 patients treated with MVD
for TN caused by veins, the pain recurred in 122 patients (31.0%). MVD is a major neurosurgical
operation that may have serious complications as well as prolonged convalescence [7].
5.4. Radiofrequency
Percutaneous radiofrequency thermocoagulation of the trigeminal ganglion (PRTTG) is an
interventional treatment that is relatively safe and patients are treated as outpatients. It is less
invasive in comparison to other invasive modes of treatment, is not very time consuming (30–
60 minutes), and has a low complication rate. Motamedi and colleagues [7] did a study from
2000 to 2006, in which data from 65 patients treated for clinically documented TN (according
to Winn’s criteria) were assessed. Out of 65 patients, 36 (55.4%) females and 29 (44.6%) males
with a mean age of 52.4 years (ranging from 21–75 years), a total of 51 (78.5%) patients were
successfully treated; 14 (21.5%) were unsuccessful. The success rate was significantly higher
for patients with defined TZs (74.5%) in comparison with those without defined TZs (25.5%).
There was no need to repeat RF for the majority (72.3%) of the patients.
5.5. Botulinum toxin injection
Several studies have documented the beneficial effects of BTX-A on reducing the frequency
and severity of TN. The actual mechanism is not well understood. Some believe that botulinum
toxin injection inhibits secretion of acetylcholine in nerve endings, leading to relaxation of
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muscles and relief of pain; others think that the injection stops secretion of nociceptive
neuropeptides in addition to acetylcholine, which helps prevent pain [9–11].
6. Conclusion
All our patients with DR-TN received 50–100 U BTX-A at each TZ. All experienced consider‐
able pain relief and some were completely cured up to the time of writing. These findings were
in accordance with the studies by Türk et al. [12] and Zúñiga et al. [13]. In both studies, the
pain attacks were considerably alleviated. Türk et al. conducted a relatively similar study, in
patients who were suffering from TN and injected with 100 U of botulinum solution below the
zygomatic arch at the involved site [12]. Zúñiga et al. injected BTX into the subcutaneous tissue
in patients suffering from TN and got good results [13]. In our study, partial paresis occurred
in 3 patients, which resolved spontaneously in 2 cases and disappeared in the third patient
after physiotherapy for 3 months. Injection of local anesthetic at the site before BTX injection
may have prevented this. In series by Türk et al., no paresis was reported and complications
were dysesthesia in one patient and difficulty in chewing in another [12]. In study by Zúñiga
et al., paresis was reported in 1 patient who recovered spontaneously. In our study, complete
cure was seen in 7 patients (1 had a 24-year history of severe pain).
In the other 8 patients, the severity and frequency of pain were reduced considerably. In all of
these patients, pain threshold improved and a stronger stimulus was necessary to provoke TN
pain, and pain attacks got weakened and duration got decreased. In conclusion, this study
supports other similar studies and shows that BTX-A is a safe minimally invasive method that
can play a role in treating TN before other more invasive therapies, i.e., radiofrequency and
surgery are sought. However, long-term assessment is still under study.
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